Clinical Trial Update: Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib, dexamethasone, and rituximab in Waldenstrom's macroglobulinemia has completed, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenstrom Macroglobulinemia

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2016-04-08